lookindex

Mazdutide

Also known as IBI362, OXM3

Approved in China, where trials show real weight loss. No regulator in the US, UK, Australia or EU has reviewed it, so anything sold in those regions is unverified.

Information only. Not medical advice. Talk to a doctor before you start, stop or change anything.

What people claim

  • Better than semaglutide
  • Approved, so it is safe to import
  • Fat loss without the nausea

What the evidence shows

  • In GLORY-1, 610 adults in China lost up to 14.0% of body weight over 48 weeks. The placebo group gained 0.3%.[1]
  • On the higher dose, 49.5% lost at least 15% of their weight, against 2.0% on placebo.[1]
  • The trial used China's lower obesity thresholds and was funded by the manufacturer. Results may not transfer directly to other populations.[1]

Known risks

  • Stomach side effects were the most common, mostly mild to moderate.[1]
  • Few stopped because of side effects: 0.5% to 1.5%, against 1.0% on placebo.[1]
  • TGA testing found unapproved peptides often do not contain what their labels claim.[2]

Reported side effects

Moderated user reports are not open yet, so nothing is shown here. They will be labelled as unverified personal accounts.

Legal status

A summary, not legal advice. Rules change, and sport bans are separate.

United States

Unapproved

Not FDA approved.

United Kingdom

Unlicensed

No licensed medicine contains it.

Australia

Not approved

TGA says importing, advertising or supplying unapproved peptides is unlawful.[3]

European Union

Not authorised

No authorised medicine. Its 2025 approval in China does not apply in the EU.[4]

Sources

  1. 1.Mazdutide in Chinese adults with obesity or overweight (GLORY-1)New England Journal of Medicine, 2025
  2. 2.TGA testing finds unapproved peptides do not contain what their labels claimTGA Australia, Nov 2026
  3. 3.Importing, compounding and supplying unapproved peptide productsTGA Australia
  4. 4.With China approval, Lilly and Innovent's mazdutide breaks into new class for GLP-1 obesity drugsFierce Pharma, Jun 2025

Profile last checked 7 Nov 2026.